130 related articles for article (PubMed ID: 1519380)
1. Cancer therapy: reimbursement of new therapeutic technologies.
Williams HM
Yale J Biol Med; 1992; 65(2):83-97. PubMed ID: 1519380
[TBL] [Abstract][Full Text] [Related]
2. European perspective on the costs and cost-effectiveness of cancer therapies.
Drummond MF; Mason AR
J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
[TBL] [Abstract][Full Text] [Related]
3. Reimbursing new technologies: why are the courts judging experimental medicine?
Saver RS
Stanford Law Rev; 1992 May; 44(5):1095-131. PubMed ID: 10119850
[No Abstract] [Full Text] [Related]
4. American Society of Clinical Oncology guidance statement: the cost of cancer care.
Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
[TBL] [Abstract][Full Text] [Related]
5. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
American Society of Clinical Oncology
J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
[TBL] [Abstract][Full Text] [Related]
6. Beware the Medical-Industrial Complex.
Stevens CW; Glatstein E
Oncologist; 1996; 1(4):IV-V. PubMed ID: 10388005
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of medical-technology strategies: effects of coverage and reimbursement (first of two parts).
Bunker JP; Fowles J; Schaffarzick R
N Engl J Med; 1982 Mar; 306(10):620-4. PubMed ID: 7035944
[No Abstract] [Full Text] [Related]
8. Medical insurance payments and patients involved in research.
Holder AR
IRB; 1994; 16(1-2):19-22. PubMed ID: 11652323
[No Abstract] [Full Text] [Related]
9. Paying for patient care in treatment research--who is responsible?
Wittes RE
Cancer Treat Rep; 1987 Feb; 71(2):107-13. PubMed ID: 3100033
[No Abstract] [Full Text] [Related]
10. On the Way to New Horizons: Telemedicine in Oncology.
Schlag PM
Oncologist; 1997; 2(2):III-IV. PubMed ID: 10388041
[TBL] [Abstract][Full Text] [Related]
11. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
12. Controlling costs by adjusting payment for medical technologies.
Hellinger FJ
Inquiry; 1982; 19(1):34-43. PubMed ID: 6461599
[No Abstract] [Full Text] [Related]
13. Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria.
Coyle D; Buxton MJ; O'Brien BJ
Health Econ; 2003 May; 12(5):421-7. PubMed ID: 12720259
[TBL] [Abstract][Full Text] [Related]
14. Health care economics of cancer in the elderly.
Bailes JS
Cancer; 1997 Oct; 80(7):1348-50. PubMed ID: 9317189
[TBL] [Abstract][Full Text] [Related]
15. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
Führlinger S
Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
[TBL] [Abstract][Full Text] [Related]
16. Who should rightfully decide whether a medical treatment necessarily incurred should be excluded from coverage under a health insurance policy provision which excludes from coverage "experimental" medical treatments?
Fisfis BA
Duquesne Law Rev; 1993; 31(4):777-800. PubMed ID: 11652669
[No Abstract] [Full Text] [Related]
17. National Authority for Health: France.
Rochaix L; Xerri B
Issue Brief (Commonw Fund); 2009 Jul; 58():1-9. PubMed ID: 19639712
[TBL] [Abstract][Full Text] [Related]
18. Policy formulation and technology assessment.
Banta HD; Behney CJ
Milbank Mem Fund Q Health Soc; 1981; 59(3):445-79. PubMed ID: 6792555
[TBL] [Abstract][Full Text] [Related]
19. Health care rationing and disability rights.
Peters PG
Indiana Law J; 1995; 70(2):491-547. PubMed ID: 11660218
[No Abstract] [Full Text] [Related]
20. Assessing medical efficacy:a neglected administrative necessity.
Hofmann PB
Hosp Prog; 1979 Oct; 60(10):45-7. PubMed ID: 113332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
